Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PIPE-307 · 2 trials · 1 indication
Number of participants with TEAEs
| Arm | Type | Description |
|---|---|---|
| PIPE-307 | EXPERIMENTAL | Subjects will receive an oral dose of PIPE-307 and 3 intravenous injections of \[11C\] PIPE- 307. |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PIPE-307 | DRUG | Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307. Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging. |
| Placebo oral tablet | DRUG | Single and multiple ascending oral doses of matching Placebo tablets |
Key Criteria: * Normotensive male or female volunteers between 25-65 years old * Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine Key Exclusion Criteria: * Clinically relevant abnormal findings at the screening asse...
PIPE-307 is an investigational small molecule being developed for Multiple Sclerosis. It is currently in Phase 1 clinical development, with studies conducted in healthy volunteers to evaluate safety, tolerability, and receptor occupancy. PIPE-307 is not yet approved and remains under investigation for this condition.
PIPE-307 targets the Muscarinic Type 1 Receptor (M1AChR). A Phase 1 PET study was conducted to determine the relationship between plasma concentrations and M1AChR occupancy of PIPE-307 in healthy volunteers, indicating that the drug is designed to interact with this receptor.
PIPE-307 is being developed by Contineum Therapeutics, Inc., a biopharmaceutical company traded under the ticker CTNM. The company is conducting Phase 1 clinical trials for this investigational drug in Multiple Sclerosis.
PIPE-307 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities for any indication.
PIPE-307 has two completed Phase 1 trials. NCT04725175 evaluated safety and tolerability of escalating single and multiple doses and food effect in 70 healthy volunteers in Australia. NCT04941781 was a PET study in 6 healthy volunteers in the United Kingdom to determine M1AChR occupancy.
PIPE-307 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information.